Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation
Site Specific Drug Delivery with Light-responsive Conjugates for Photo-biomodulation
批准号:
10735978
负责人:
Youngjae You
金额:
$34.23万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-03-01 至 2027-07-31
关键词:
AminesAnimal Cancer ModelBiological ProcessBreast Cancer ModelCancer Vaccine Related DevelopmentCancer VaccinesCellsChemicalsChemistryClinicalColon CarcinomaDevelopmentDiseaseDisseminated Malignant NeoplasmDrug ControlsDrug Delivery SystemsDrug KineticsEvaluationGlioblastomaGoalsImmuneImmune checkpoint inhibitorImmune responseImmune systemImmunologic AdjuvantsImmunologic StimulationImmunotherapeutic agentIn SituKineticsLightLightingLocalized DiseaseLocationMalignant NeoplasmsMalignant neoplasm of pancreasMalignant neoplasm of urinary bladderMathematicsMechanicsMetastatic/RecurrentModelingMusNeoplasm MetastasisOrganPUVA PhotochemotherapyPatientsPharmaceutical PreparationsPharmacodynamicsPhotochemistryPhotosensitizing AgentsPhysiologicalPre-Clinical ModelRattusReactionRecurrenceResolutionSinglet OxygenSiteSystemTestingTherapeuticTimeTissuesTreatment Side EffectsTumor AntigensUltraviolet RaysVaccinationValidationVisible Radiationanti-canceranti-tumor immune responseantitumor effectbiomaterial compatibilitybody systemchemical conjugatechemical synthesischemotherapyclinical applicationcytokinedesigndisorder controlimmune activationimmunogenicimmunoregulationin situ vaccinationinnovationinsightinterstitialmalignant breast neoplasmmelanomapharmacodynamic modelpharmacologicphotobiomodulationprophylacticresponseside effectspatiotemporaltooltumortumor microenvironmenttumor-immune system interactionsvaccination strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/ Abstract
Light is an exceptional tool in disease treatment, offering precise controllability in treatment time and location.
Unlike UV light, longer visible and near infrared (IR) light is not toxic and reaches deeper tissues than UV for
clinical applications. However, chemical linkers that are cleavable by such biocompatible light are very scarce.
Long term goals are to develop chemical linkers that are cleaved by visible and near IR light for light-controlled
drug delivery, and to design and synthesize chemical conjugates that are used for pho-biomodulation. In the
previous project, a drug conjugate platform and photo-release strategy for site specific drug delivery were
established. Click and photo-unclick chemistry was demonstrated, where singlet oxygen (SO)-cleavable linker
is synthesized via amine-yne click reaction and cleaved by SO. The drug conjugates are composed of drug, SO-
cleavable linker, photosensitizer and cancer-targeting group. When illuminated with red light (690 nm), the
conjugates generate SO and release drug only in the illuminated region and treat the disease locally. In the next
5 years, a bolder photo-biomodulation strategy will be established using the light-responsive drug conjugate
platform. Overarching hypothesis is that local photo-biomodulation using visible and near IR light-responsive
conjugates can make systemic pharmacological effects via activation of immune system. Main goals in this
application are to design and prepare SO-cleavable conjugates of immunostimulant drugs and to prove that this
visible-light responsive conjugates can be used for generating systemic and tumor-specific anticancer effects.
The conjugates are activated by a focused local illumination, release drugs site-specifically, and stimulate
immune system to trigger systemic and tumor-specific immune responses. The systemic antitumor effect is
further enhanced by the combination with systemically administered drugs with non-overlapping mechanisms
with the local photo-biomodulation. The goals are realized with 3 specific aims: (1) Design and prepare SO-
activatable conjugates of immune-stimulating drugs and determine systemic antitumor effects, (2) Determine the
mechanisms of systemic effects of the photo-biomodulation and establish the immuno-pharmacodynamics, (3)
Determine the enhanced systemic antitumor effect of the local photo-biomodulation by adding clinically available
checkpoint inhibitors. Pharmacokinetic and immune-pharmacodynamic modeling is used for analyzing and
simulating dynamic changes of conjugates, released drugs, and immune cells in various tissues to gain
mechanistic insight at the systemic level. Major deliverables are (i) red-light responsive conjugates of
immunostimulant drugs, (ii) immune-pharmacodynamic models following photo-biomodulation, and (iii) validation
of our local photo-biomodulation for systemic effects. The strategy is tested using breast and colon cancer animal
models but it could be applicable for a wide range of tumors using interstitial or external illumination.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Anticancer drug released from near IR-activated prodrug overcomes spatiotemporal limits of singlet oxygen.
近红外激活原药释放的抗癌药物克服了单线态氧的时空限制。
DOI:
10.1016/j.bmc.2016.02.025
发表时间:
2016-04-01
期刊:
Bioorganic & medicinal chemistry
影响因子:
3.5
作者:
[Rajaputra P, Bio M, Nkepang G, Thapa P, Woo S, You Y]
通讯作者:
You Y
DOI:
10.1007/s10928-017-9543-z
发表时间:
2017-12
期刊:
Journal of pharmacokinetics and pharmacodynamics
影响因子:
2.5
作者:
[Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S]
通讯作者:
Woo S
DOI:
10.1021/acsomega.7b01105
发表时间:
2017-10-31
期刊:
ACS omega
影响因子:
4.1
作者:
[Thapa P, Li M, Karki R, Bio M, Rajaputra P, Nkepang G, Woo S, You Y]
通讯作者:
You Y
DOI:
10.1111/php.13202
发表时间:
2020-05
期刊:
Photochemistry and photobiology
影响因子:
3.3
作者:
[Subramaniyan B, Rajaputra P, Nguyen L, Li M, Peer CJ, Kindrick J, Figg WD, Woo S, You Y]
通讯作者:
You Y
Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy.
紫杉醇的远红色轻度前药,用于光动力疗法和特定部位特异性紫杉醇化学疗法的综合作用。
DOI:
10.1021/acs.jmedchem.5b01971
发表时间:
2016-04-14
期刊:
JOURNAL OF MEDICINAL CHEMISTRY
影响因子:
7.3
作者:
[Thapa, Pritam, Li, Mengjie, Bio, Moses, Rajaputra, Pallavi, Nkepang, Gregory, Sun, Yajing, Woo, Sukyung, You, Youngjae]
通讯作者:
You, Youngjae
共 6 条
Singlet Oxygen-cleavable Prodrugs for Treating Non-Muscle Invasive Bladder Cancers
-
批准号:10665068
-
项目类别:
-
资助金额:$41.13万
-
财政年份:2022
-
负责人:Youngjae You
-
依托单位:
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers
-
批准号:10056534
-
项目类别:
-
资助金额:$14.76万
-
财政年份:2015
-
负责人:Youngjae You
-
依托单位:
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers
-
批准号:9263824
-
项目类别:
-
资助金额:$12.89万
-
财政年份:2015
-
负责人:Youngjae You
-
依托单位:
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers
-
批准号:9207769
-
项目类别:
-
资助金额:$30.34万
-
财政年份:2015
-
负责人:Youngjae You
-
依托单位:
NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers
-
批准号:9023578
-
项目类别:
-
资助金额:$10.86万
-
财政年份:2015
-
负责人:Youngjae You
-
依托单位: